Amylyx preps filing for its ALS drug after FDA feedbackJust a few months ago, Amylyx was talking about having to complete another clinical trial before it could Share XAmylyx preps filing for its ALS drug after FDA feedbackhttps://pharmaphorum.com/news/amylyx-preps-filing-for-its-als-drug-after-fda-feedback/
First subject dosed in psilocybin trial for rare headache disorderThe first patient has received a low dose of Beckley Psytech’s psychedelic medicine psilocybin in a clinical trial Share XFirst subject dosed in psilocybin trial for rare headache disorderhttps://pharmaphorum.com/news/first-subject-dosed-in-psilocybin-trial-for-rare-headache-disorder/
Startup Neuroglee raises $10m for virtual neurology clinicsA digital health company focusing on neurodegenerative disorders – Neuroglee Therapeutics – has raised $10 million in first-round Share XStartup Neuroglee raises $10m for virtual neurology clinicshttps://pharmaphorum.com/news/startup-neuroglee-raises-10m-for-virtual-neurology-clinics/
Server cans autism hope bumetanide after phase 3 failsServier and Neurochlore have been forced to admit defeat in their bid to bring the first drug to Share XServer cans autism hope bumetanide after phase 3 failshttps://pharmaphorum.com/news/server-cans-autism-hope-bumetanide-after-phase-3-fails/
AC Immune claims half a win for tau drug in Alzheimer’s trialShares in AC Immune leaped today after the company said its tau-targeting Alzheimer’s disease candidate semorinemab hit one Share XAC Immune claims half a win for tau drug in Alzheimer’s trialhttps://pharmaphorum.com/news/ac-immune-claims-half-a-win-for-tau-drug-in-alzheimers-trial/
Beckley Psytech raises $80m for psychedelic meds developmentUK psychedelic medicine specialist Beckley Psytech has raised an impressive £58 million (around $80 million) in an oversubscribed Share XBeckley Psytech raises $80m for psychedelic meds developmenthttps://pharmaphorum.com/news/beckley-psytech-raises-80m-for-psychedelic-meds-development/
Lilly sets out its stall on donanemab as filing approachesThe FDA’s approval of Biogen’s Aduhelm for Alzheimer’s disease has emboldened Eli Lilly to move forward plans to Share XLilly sets out its stall on donanemab as filing approacheshttps://pharmaphorum.com/news/lilly-sets-out-its-stall-on-donanemab-as-filing-approaches/
AbbVie, Calico raise their age-related disease alliance funding to $3.5bnAbbVie and Alphabet spin-out Calico Life Sciences have agreed to fund their seven-year-old partnership seeking treatments for diseases Share XAbbVie, Calico raise their age-related disease alliance funding to $3.5bnhttps://pharmaphorum.com/news/abbvie-calico-raise-their-age-related-disease-alliance-funding-to-3-5bn/
Biogen bites back at critics of Aduhelm after drug’s slow startBiogen has reported $2m in sales for newly-launched Alzheimer’s therapy Aduhelm that came in below its expectations, prompting Share XBiogen bites back at critics of Aduhelm after drug’s slow starthttps://pharmaphorum.com/news/biogen-bites-back-at-critics-of-aduhelm-after-drugs-slow-start/
